Pharma IQ Members

Center For Biologics Evaluation and Research (CBER)

The Center For Biologics Evaluation and Research (CBER) is the Center within FDA that regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.

Improving the Security, Quality & Compliance of your Biologic Operation

In the coming years, biologics are expected to make up a greater proportion of revenue growth for pharmaceutical companies, with some figures placing it as high as 60 per cent.  The US Food and Drug Administration last year approved a total of 24...

Contributor: Pharma IQ
02/20/2012 07:00:00 PM EST
Pharma IQ

Working as a clinical research coordinator or a clinical research associate can prove both a challenging and rewarding career. Those who excel in the profession often have strong scientific knowledge, excellent organisational skills and the...

Contributor: Pharma IQ
08/30/2010 08:00:00 PM EDT
Pharma IQ

Pharma IQ chats with Eileen Edmonson, Pipeline and Hazardous Materials Safety Administration, U.S. Department of Transportation, about navigating the U.S. Department of Transportation’s regulations for biologics and biological agents.

Contributor: Pharma IQ
04/19/2010 08:00:00 PM EDT